Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 1/20 | 0.46 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.43 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.42 |
| ▸ | EED | O75530 | 1/20 | 0.42 |
| ▸ | RBBP4 | Q09028 | 1/20 | 0.42 |
| ▸ | SUZ12 | Q15022 | 1/20 | 0.42 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.42 |
| ▸ | AEBP2 | Q6ZN18 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | STAT3 | P40763 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.41 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16036752 | 1.00 | ABCB1 (0.46) | ABCB1UTS2RP2RX7EEDRBBP4 | |
| SCHEMBL19946452 | 0.90 | TAS1R3 (0.48) | ABCB1UTS2RP2RX7EEDRBBP4 | |
| SCHEMBL2682576 | 0.90 | TAS1R3 (0.48) | ABCB1UTS2RP2RX7EEDRBBP4 | |
| SCHEMBL668773 | 0.88 | TAS1R3 (0.44) | ABCB1UTS2RP2RX7EEDRBBP4 | |
| SCHEMBL22380835 | 0.88 | TAS1R3 (0.44) | ABCB1UTS2RP2RX7EEDRBBP4 | |
| SCHEMBL3774894 | 0.86 | TAS1R3 (0.42) | ABCB1UTS2RP2RX7EEDRBBP4 | |
| SCHEMBL2778946 | 0.86 | ABCB1 (0.43) | ABCB1UTS2RP2RX7EEDRBBP4 | |
| SCHEMBL2681461 | 0.86 | ABCB1 (0.43) | ABCB1UTS2RP2RX7EEDRBBP4 | |
| SCHEMBL668846 | 0.84 | P2RX7 (0.40) | UTS2RP2RX7RAB9ALMNANPC1 | |
| SCHEMBL17625005 | 0.80 | CTSS (0.36) | TAS1R3TAS1R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10851119-B2 | Boron-containing diacylhydrazines | INTREXON CORPORATION (US) | 2020-12-01 | — | — | US | disclosed |
| US-20200157122-A1 | BORON-CONTAINING DIACYLHYDRAZINES | INTREXON CORP (US) | 2020-05-21 | — | — | US | disclosed |
| CN-107406373-B | Boron-containing diacylhydrazine compounds | 英特瑞克斯顿股份有限公司 | 2020-04-28 | — | — | CN | disclosed |
| EP-3194359-B1 | BORON-CONTAINING DIACYLHYDRAZINE COMPOUNDS | INTREXON CORP (US) | 2020-04-08 | — | — | EP | disclosed |
| US-10570158-B2 | Boron-containing diacylhydrazine compounds | INTREXON CORPORATION (US) | 2020-02-25 | — | — | US | disclosed |
| US-10464951-B2 | Boron-containing diacylhydrazines | INTREXON CORPORATION (US) | 2019-11-05 | — | — | US | disclosed |
| US-20180201628-A1 | Boron-Containing Diacylhydrazine Compounds | INTREXON CORP (US) | 2018-07-19 | — | — | US | disclosed |
| EP-2970106-B1 | BORON-CONTAINING DIACYLHYDRAZINES | INTREXON CORP (US) | 2018-05-16 | — | — | EP | disclosed |
| US-9944659-B2 | Boron-containing diacylhydrazine compounds | INTREXON CORPORATION (US) | 2018-04-17 | — | — | US | disclosed |
| US-20180079759-A1 | Boron-Containing Diacylhydrazines | INTREXON CORPORATION (US) | 2018-03-22 | — | — | US | disclosed |
| US-7563928-B2 | Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2009-07-21 | — | — | US | disclosed |
| US-7563928-B2 | Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2009-07-21 | — | — | US | disclosed |
| US-7563928-B2 | Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2009-07-21 | — | — | US | disclosed |
| US-7456315-B2 | Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2008-11-25 | — | — | US | disclosed |
| US-7456315-B2 | Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2008-11-25 | — | — | US | disclosed |
| US-7456315-B2 | Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2008-11-25 | — | — | US | disclosed |
| US-20080064741-A1 | BIOAVAILABLE DIACYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | RHEOGENE, INC. | 2008-03-13 | — | — | US | disclosed |
| US-20080064741-A1 | BIOAVAILABLE DIACYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | RHEOGENE, INC. | 2008-03-13 | — | — | US | disclosed |
| US-20080064741-A1 | BIOAVAILABLE DIACYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | RHEOGENE, INC. | 2008-03-13 | — | — | US | disclosed |
| US-20060020146-A1 | Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | RHEOGENE, INC. | 2006-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10464951-B2 | Boron-containing diacylhydrazines | CD22, BRDT, BCR | ABCB1 464/4885UTS2R 1725/4885P2RX7 4296/4885 |
| US-20180201628-A1 | Boron-Containing Diacylhydrazine Compounds | BRDT, CD22, BCR | ABCB1 279/4885UTS2R 1812/4885P2RX7 4331/4885 |
| US-10851119-B2 | Boron-containing diacylhydrazines | CD22, BRDT, BCR | ABCB1 464/4885UTS2R 1725/4885P2RX7 4296/4885 |
| US-20080064741-A1 | BIOAVAILABLE DIACYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | NR2E3, NR5A1, NR5A2 | ABCB1 1365/4885UTS2R 176/4885P2RX7 3485/4885 |
| US-20200157122-A1 | BORON-CONTAINING DIACYLHYDRAZINES | CD22, BRDT, BCR | ABCB1 464/4885UTS2R 1725/4885P2RX7 4296/4885 |
| US-20060020146-A1 | Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | NR2E3, NR5A1, NR5A2 | ABCB1 1365/4885UTS2R 176/4885P2RX7 3485/4885 |
| US-10570158-B2 | Boron-containing diacylhydrazine compounds | BRDT, CD22, BCR | ABCB1 279/4885UTS2R 1812/4885P2RX7 4331/4885 |
| US-20180079759-A1 | Boron-Containing Diacylhydrazines | CD22, BRDT, BCR | ABCB1 464/4885UTS2R 1725/4885P2RX7 4296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.